1. Home
  2. HTLM vs UPB Comparison

HTLM vs UPB Comparison

Compare HTLM & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTLM
  • UPB
  • Stock Information
  • Founded
  • HTLM 2014
  • UPB 2021
  • Country
  • HTLM Singapore
  • UPB United States
  • Employees
  • HTLM N/A
  • UPB N/A
  • Industry
  • HTLM
  • UPB
  • Sector
  • HTLM
  • UPB
  • Exchange
  • HTLM NYSE
  • UPB NYSE
  • Market Cap
  • HTLM 153.9M
  • UPB 1.0B
  • IPO Year
  • HTLM 2024
  • UPB 2024
  • Fundamental
  • Price
  • HTLM $9.65
  • UPB $16.30
  • Analyst Decision
  • HTLM
  • UPB Strong Buy
  • Analyst Count
  • HTLM 0
  • UPB 4
  • Target Price
  • HTLM N/A
  • UPB $56.50
  • AVG Volume (30 Days)
  • HTLM 162.9K
  • UPB 460.2K
  • Earning Date
  • HTLM 02-15-2025
  • UPB 02-14-2025
  • Dividend Yield
  • HTLM N/A
  • UPB N/A
  • EPS Growth
  • HTLM N/A
  • UPB N/A
  • EPS
  • HTLM N/A
  • UPB N/A
  • Revenue
  • HTLM $4,563,246.00
  • UPB $2,207,000.00
  • Revenue This Year
  • HTLM N/A
  • UPB N/A
  • Revenue Next Year
  • HTLM N/A
  • UPB N/A
  • P/E Ratio
  • HTLM N/A
  • UPB N/A
  • Revenue Growth
  • HTLM N/A
  • UPB 82.10
  • 52 Week Low
  • HTLM $2.57
  • UPB $14.97
  • 52 Week High
  • HTLM $13.74
  • UPB $29.46
  • Technical
  • Relative Strength Index (RSI)
  • HTLM N/A
  • UPB N/A
  • Support Level
  • HTLM N/A
  • UPB N/A
  • Resistance Level
  • HTLM N/A
  • UPB N/A
  • Average True Range (ATR)
  • HTLM 0.00
  • UPB 0.00
  • MACD
  • HTLM 0.00
  • UPB 0.00
  • Stochastic Oscillator
  • HTLM 0.00
  • UPB 0.00

About HTLM HOMESTOLIFE LTD

Homestolife Ltd is a home furniture retailers that offers and sells customized furniture solutions in Singapore. It has six retail store locations that sell furniture manufactured from China and other Asian countries.

About UPB UPSTREAM BIO INC

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.

Share on Social Networks: